Cannabis Report
Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568, CashBowski, Duke_DD_em, cleantrader, BullsOnFire, BlissTaxi
Search This Board: 
Last Post: 5/21/2018 4:19:28 PM - Followers: 181 - Board type: Free - Posts Today: 87


The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.

What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 


Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   

GT Biopharma Portfolio

GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.

Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."


Company Website

GTBP Investor's Overview


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Quarterly Report (10-q) 05/15/2018 06:12:45 PM
GTBP News: Current Report Filing (8-k) 05/14/2018 04:04:20 PM
GTBP News: Current Report Filing (8-k) 04/27/2018 04:03:53 PM
GTBP News: Notice of Effectiveness (effect) 03/23/2018 06:02:07 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#12944  Sticky Note GTBP (GTBP) Announces Dr. Urbanski Elevated to President cleantrader 05/14/18 09:57:42 AM
#12195  Sticky Note DUKE's MASSIVE DD POST ON $GTBP or HOW Duke_DD_em 05/04/18 08:56:30 PM
#11766  Sticky Note $GTBP Exec Team Stacked with Superstars. The Duke_DD_em 05/01/18 02:58:41 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#13555   GTBP have such a quality product, concept, management Level Up 05/21/18 04:19:28 PM
#13554   We will see more this days to come AntMiner 05/21/18 04:17:47 PM
#13553   I agree Level Up 05/21/18 04:17:05 PM
#13552   true AntMiner 05/21/18 04:16:53 PM
#13551   yes this is a buying time before the AntMiner 05/21/18 04:16:11 PM
#13550   The volume was not enough for taking ground Level Up 05/21/18 04:11:59 PM
#13549   Looks like some consolidation day Level Up 05/21/18 04:11:27 PM
#13548   We need here some recovery Level Up 05/21/18 04:07:15 PM
#13547   NEW HERE? -Be sure to check out their AntMiner 05/21/18 03:35:29 PM
#13546   Still churning here around $1.60 and neutral AntMiner 05/21/18 03:34:59 PM
#13545   A revolutionary system here for change the complete concept Level Up 05/21/18 03:29:05 PM
#13544   Power Hour cone on Level Up 05/21/18 03:25:43 PM
#13543   What is Immuno Oncology? Immuno Oncology is treatment AntMiner 05/21/18 03:06:05 PM
#13542   Cancer is the second leading cause of death AntMiner 05/21/18 03:05:51 PM
#13541   $GTBP's Executive Team Is Stacked With BioMedical Superstars AntMiner 05/21/18 03:05:29 PM
#13540   Neutral but solid, this will jump in PH! AntMiner 05/21/18 03:02:52 PM
#13539   Power Hour guys! AntMiner 05/21/18 03:01:02 PM
#13538   $1.51 - Perfect entry to buy here in cryptojacko 05/21/18 02:25:35 PM
#13537   $GTBP is the most undervalued gem in the cryptojacko 05/21/18 02:23:52 PM
#13536   $GTBP has a bright future we all know this cryptojacko 05/21/18 02:19:48 PM
#13535   I'm maybe a newbie but I did my BearKnuckle 05/21/18 02:12:50 PM
#13534   Agreed. GTBP has way too much going on BearKnuckle 05/21/18 02:11:33 PM
#13533   I think with new update OXS-3550 IND Filing cryptojacko 05/21/18 02:09:25 PM
#13532   GTBP is rocking! Kiko4Me 05/21/18 02:08:46 PM
#13531   exactly crypto Kiko4Me 05/21/18 02:08:10 PM
#13530   They have the right experts on the executive BearKnuckle 05/21/18 01:53:30 PM
#13529   Heres a good intro to the $GTBP offering cryptojacko 05/21/18 01:47:30 PM
#13528   Great post. I agree theres a lot of cryptojacko 05/21/18 01:39:40 PM
#13527   Excellent explanation CJ! imho breakthroughs in immuno-oncology are BearKnuckle 05/21/18 01:31:40 PM
#13526   Well said. billymack 05/21/18 01:30:04 PM
#13525   Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy cryptojacko 05/21/18 01:26:28 PM
#13524   People are always searching for an OTC that BearKnuckle 05/21/18 01:22:24 PM
#13523   "expected in 2H ‘18." billymack 05/21/18 01:19:08 PM
#13522   A strong PR about the progress of NASDAQ cryptojacko 05/21/18 01:15:00 PM
#13521   $GTBP, one of the most overvalued OTC plays BearKnuckle 05/21/18 01:11:01 PM
#13520   Immuno-oncology, one of the pillars of cancer treatment, BearKnuckle 05/21/18 01:09:56 PM
#13519   Me too and I agree GTBP long LivH 05/21/18 01:07:04 PM
#13518   What is Immuno Oncology? Immuno Oncology is treatment cryptojacko 05/21/18 01:05:21 PM
#13517   OXS-1550 uses a proprietary immunoconjugate platform technology, as BearKnuckle 05/21/18 01:03:05 PM
#13516   OXS-1550 is like smart missile against cancer! $GTBP cryptojacko 05/21/18 12:42:42 PM
#13515   Based on my limited analysis, OXS-3550 TRiKe looks BearKnuckle 05/21/18 12:40:35 PM
#13514   if OXS-1550 or OXS-3550 are approved, the company cryptojacko 05/21/18 12:29:58 PM
#13513   $GTBP drug pipeline. OXT-1550 is currently in phase BearKnuckle 05/21/18 12:26:21 PM
#13512   Agreed!IMHO $GTBP soon will turn into a leading cryptojacko 05/21/18 12:19:17 PM
#13511   Been watching this stock for a while, I BearKnuckle 05/21/18 12:09:46 PM
#13510   GT Biopharma, Inc. is a biotechnology company focused cryptojacko 05/21/18 10:46:10 AM
#13509   GTBP just as I was thinking strong Intra cryptojacko 05/21/18 10:36:20 AM
#13508   Immuno Oncology is the Future of Cancer Treatment! cryptojacko 05/21/18 10:32:29 AM
#13507   Yeah, I like how the company has done cryptojacko 05/21/18 10:26:44 AM
#13506   &1.90 this week? Level Up 05/21/18 10:20:52 AM